▶주메뉴 바로가기

▶본문 바로가기

THE INVESTOR
April 09, 2020
Big Reunion

Stocks & Bonds

[EQUITIES] ‘Yuhan’s Q3 earnings very disappointing’

  • PUBLISHED :October 31, 2018 - 10:37
  • UPDATED :October 31, 2018 - 10:37
  • 폰트작게
  • 폰트크게
  • facebook
  • twitter
  • sms
  • print

[THE INVESTOR] Yuhan’s earnings in the third quarter have been a major disappointment, said SK Securities on Oct. 31 lowering the target price to 230,000 won (US$201.77) from 300,000 won.




Its operating profit has tumbled from increasing R&D and personnel costs as well as swelling losses of subsidiaries. Although revenue will return to an upward cycle in the fourth quarter when it releases a new product, costs will continue to rise due to its growing pipeline, said analyst Lee Dal-mi.

Its most promising new drug candidate, a treatment for non-small cell lung cancer, will complete second-phase clinical trials within this year and will be rolled out provisionally next year in Korea. There still remains expectations for a license-out deal, she added maintaining a “buy” recommendation. 

By Hwang You-mee (glamazon@heraldcorp.com)

  • facebook
  • twitter
  • sms
  • print

EDITOR'S PICKS